Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29-41.Coombs CC, Tallman MS, Levine RL. Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol. 2015. doi: 10.1038/nrclinonc.2015.210....
Post-remission or remission continuation therapy (called consolidation therapy in the past).After you have achieved remission, this therapy aims to kill any remaining leukemia cells so the cancer doesn’t come back (relapse). In some cases, you may not be able to have post-remission therapy. ...
Acute myeloid leukemia[38] Paclitaxel-resistant of gastric cancer[40] Idiopathic cardiomyopathy[42] Inflammation or sepsis[6–8,43,44] Neuropsychiatric diseases[3,45,46] View article Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy ...
Therapy-related myelodysplasia and acute myeloid leukemiaSmita Bhatia, MD, MPH [Professor and Chair]Department of Population Sciences Ruth Ziegler Chair in Population Research City of HopeComprehensive Cancer Center Duarte, CAAbstractTherapy-related leukemia (t-MDS/AML) is a well known complication of...
Therapy for acute myeloid leukemia in older and unfit adults HaematologicaMark ForsbergMarina Konopleva
et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. 123, 4027–4036 (2014). Metzeler, K. H. et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 26, ...
Intensified Therapy for Acute Myeloid Leukemia.doi:10.1056/NEJM199410063311411Editorial. Comments on a report by Mayer, et al in the October 6, 1994 issue of 'The New England Journal of Medicine,' of a clinical trial that examined the effect of the dose of cytarabine given as post-remission ...
WHAT IS VYXEOS? VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)....
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhi
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group r... A randomized study compared the combination of amsacrine (100 mg/m2/d on days 1 to 5) and etoposide (200 mg/m2/d on days 1 to 3)...